Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting ...

Greetings, and welcome to the Incyte's Fourth Quarter and Year-End 2025 Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.8% in the morning session after the company reported mixed fourth-quarter 2025 results, where a significant revenue beat was ...

Fintel reports that on November 24, 2025, Barclays maintained coverage of Incyte (NasdaqGS:INCY) with a Overweight recommendation. Analyst Price Forecast Suggests 7.38% Downside As of November 17, ...

We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...

Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy. RBC Capital retained its Sector Perform rating on Incyte Corporation (NASDAQ:INCY) and increased its price target from $72 ...

The Beginning After the End is a 2025 anime that became notorious for its perceived mishandling of a webcomic written by a non-Japanese author. While Japanese studios are constantly adapting classic ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...

Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode. [Operator ...